Supplementary Material for: Prenatal Infection Decreases Calbindin, Decreases Purkinje Cell Volume and Density and Produces Long-Term Motor Deficits in Sprague-Dawley Rats by Wallace K. (4120819)

“…Pups in the <i>E. coli</i> group also had a decrease in the number of Purkinje cells, as well as a decrease in Purkinje cell density and volume. …”

Cannabis smoke exposure decreases locomotor activity and rearing in the small open field. by Adriaan W. Bruijnzeel (2605954)

Decrease in the number of intestinal pDCs in <i>Enpp3</i>^<i>-/-</i> mice. by Yoki Furuta (3772735)

Cooperativity decreases with the expression level of CheA. by Stephan Eismann (835052)

Frequency distribution of the hourly ERA5 reanalysis vs observations illustrating the best score (a: W02 station and b: W11 station) and the poorest score (c: W18 station and b: W1... by Weidong Ji (129916)

S5 Fig - by Jordan K. Abbott (8934239)

Variability is correlated with increasing repeat length, increasing purity, and decreasing unit size. by John W. Fondon III (145820)

Mutation of Ser-473 in GC-A to alanine but not glutamate decreases ANP-stimulated guanylyl cyclase activity. by Andrea R. Yoder (165684)

Early increase and later decrease in GSK-3β activity. by Arie J. Hoogendijk (353624)

Conventional dynamic latch comparator [13], [14]. by Labonnah Farzana Rahman (641767)

Subjects:

Performance comparison of the proposed dynamic latch comparator. by Labonnah Farzana Rahman (641767)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Table_5_Episodic Decrease in Temperature Increases mcy Gene Transcription and Cellular Microcystin in Continuous Cultures of Microcystis aeruginosa PCC 7806.XLSX by Robbie M. Martin (4686418)

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects: